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importers of antimicrobial medicines are: India (25,8%), Russia (16%), China (9.7%), 
Ukraine (9.7 %), France (6.5 %), and manufacturers from other countries consisted 
- 3,2%. CONCLUSIONS: A large part of the drugs purchased within the guaran-
teed volume of free medical aid in the Republic of Kazakhstan consist from basic 
beta-lactam antibiotics. In the list were presented the outdated drugs (gentamicin), 
which is not recommended for use. Predominant drug are drugs from domestic 
pharmaceutical companies.
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OBJECTIVES: Despite all the control efforts, Malaysia has yet to effectively reduce 
the incidence rate of tuberculosis(TB). TB is not only highly contagious but also 
causing a significant economic burden in the order of USD16 million/year as 
reported by World Health Organization(WHO) in 2014. This study aimed to evalu-
ate the economic impact of TB control in Malaysia using a dynamic transmission 
model. METHODS: Prior to model building, a disease burden study was performed 
in the state of Selangor representing 18% of the Malaysian population. Identified 
patient medical records from public hospitals and clinics were randomly selected 
for study. All direct costs of TB management were captured for analysis. A dynamic 
transmission model was built to project future disease and economic burdens over 
a 10-year period. The study was performed from a government perspective. All costs 
are expressed as USD median (interquartile range). A 3% discount rate was used 
for projections. RESULTS: A total of 436 successfully treated cases were included 
in this study. Of these, 195(44.7%) cases required hospitalisation during treatment 
period. USD616(487-763)/patient was used for non-hospitalisation cases compared 
to USD1,848(1,164-3,284)/patient for those requiring hospitalisation representing 
a 3-fold increase. 119 incomplete treatment cases were selected for comparison. 
USD337(193-902)/patient was used for these incomplete cases. Our model suggests 
that the total TB cases will increase by 65% in 10 years’ time. Using the baseline TB 
population in 2011, an estimated total of USD22.9 million(15.5-37.6 million)/year was 
used for direct medical costs. Based on a local estimated 6.9% incompletion treat-
ment rate, an extra USD5.3 million(3.5-8.6 million)/year (22.9% increase) would be 
required by 2021. CONCLUSIONS: Our findings are consistent with WHO report. In 
Malaysia, hospitalisation appears to be the major cost driver for TB patients receiv-
ing treatment. Healthcare strategies such as early detection, increased awareness of 
TB and improved compliance may potentially reduce TB health budget.
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OBJECTIVES: Differences in vaccine schedules may result in additional costs beyond 
the differences due to pricing variation between two products. There are two oral 
rotavirus vaccines approved for use in Canada; one vaccine is approved as a two-
dose schedule while the other is approved as a three-dose schedule. The objective of 
this study is to explore the cost of administration of a single dose of either rotavirus 
vaccine in each Canadian province as well as for the country overall. METHODS: Two 
extremes were considered: Every dose administered by a physician either (i) requires 
a visit solely for that purpose (cost = administration + visit), or (ii) occurs as part of 
a regular visit (cost = administration only). All costs were derived from the relevant 
fee for service agreement of each province and territory in Canada. Assumptions 
included 90% vaccine coverage across each province’s 2013 birth cohort and no 
significant changes since 2007 to the ratio of physicians to public health nurses 
(PHN) administering vaccines in each province. Delivery by PHN was assumed to 
incur no cost. RESULTS: Scenarios (i) and (ii) above yielded administration costs 
of $6.4M and $600k, respectively, per vaccinated Canadian cohort. Provinces with 
high percentage of physician delivery accounted for the majority of this cost in 
both Scenario (i) (NL: $128.6k, NB: $279.3k, NS: $312.1k, QC: $832.5k, ON: $3.8M, MB: 
$386.3k, BC: $544.1k) and Scenario (ii) (NB: $60.4k, NS: $114.2k, QC: $258.8k, MB: 
$85.1k, BC: $72.8k). CONCLUSIONS: Administration fees can be a costly factor in 
universal immunization schedules. As such, it is essential to account for the differ-
ences in approved administration schedule when evaluating vaccines during the 
assessment of publically funded program implementation.
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OBJECTIVES: Infections caused by multi-drug resistant (MDR) Acinetobacter bau-
mannii (AB) are an increasing global problem. Several studies examining outcomes 
and resource utilization associated with MDRAB have been conducted; however, 
findings are inconsistent. The purpose of this research was to identify and charac-
terize available research concerning resource utilization associated with MDRAB, 
assess strengths and weaknesses of the available research and identify future 
research priorities. METHODS: A systematic review of the literature was conducted 
using MEDLINE and electronically available conference abstracts. Articles were con-
sidered relevant if they reported resource utilization or cost information comparing 
MDRAB patients to controls. Controls could include susceptible AB, other organisms, 
or uninfected patients. RESULTS: Initial searches of the literature returned 204 
potential citations for inclusion. Title and abstract review excluded 171 articles, 
and full-text review excluded 20 additional articles, leaving a total of 13 articles 
eligible for data abstraction and review. Length of stay (LOS) was reported in nine 
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OBJECTIVES: Most patients admitted to hospital for ABSSSI complete antibacte-
rial treatment following discharge. This study examined the potential impact of 
tedizolid versus linezolid on antibacterial DOT, based on real-world inpatient use 
of linezolid in patients hospitalized for ABSSSI, and two pivotal phase 3 studies of 
patients with ABSSSI that demonstrated comparable efficacy and safety between 
a 6-day course of tedizolid (once daily) and a 10-day course of linezolid (twice 
daily). METHODS: Duration of in-hospital therapy for ABSSSI was based on analyses 
of an electronic database containing comprehensive clinical records on ~38 million 
inpatient admissions from > 100 contributing general, acute-care US hospitals. All 
patients aged ≥ 18 years admitted during 2011 with a principal diagnosis consistent 
with ABSSSI who received ≤ 10 inpatient DOT with linezolid were identified. Total 
DOT for linezolid and tedizolid (i.e., inpatient + outpatient) were assumed to be 10 
and 6 days, respectively. Patients receiving < 10 days of in-hospital therapy with lin-
ezolid were assumed to receive the remainder as outpatients; corresponding values 
for tedizolid were estimated assuming a 6-day DOT. Patients receiving ≤ 6 inpatient 
DOT with linezolid were modeled to receive the same number of inpatient days of 
tedizolid; patients with > 6 days of in-hospital therapy with linezolid were modeled 
as completing a course of tedizolid in hospital. RESULTS: Among the 3,734 ABSSSI 
patients who met study entry criteria, 153 (4%) received linezolid. Mean inpatient 
DOT was 3.7 days; consequently, expected duration of outpatient therapy was 6.3 
days. Use of tedizolid instead of linezolid was estimated to reduce average inpatient 
DOT by 0.2 days and outpatient DOT by 3.8 days. CONCLUSIONS: Based on real-
world use of linezolid for ABSSSI and findings from tedizolid pivotal trials, use of 
tedizolid in hospitalized patients with ABSSSI may substantially reduce mean total 
DOT compared with linezolid, primarily on an outpatient basis.
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OBJECTIVES: The objective of this study is to examine the decisive factors associated 
with the use of antiretroviral therapy (ART) among a Human Immunodeficiency 
Virus (HIV) infected population utilizing Andersen’s Behavioral Model. METHODS: 
This study is a retrospective data analysis of individuals infected with HIV in panels 
14 to 16 of the Medical Expenditure Panel Survey in years 2009 to 2012. A logistic 
regression analysis was conducted to evaluate the association between ART usage 
and the factors nested in Andersen’s Behavioral Model, which includes predispos-
ing, enabling and need components. RESULTS: For predisposing characteristics, 
patients taking ART were slightly older (age: 46.14±0.98) than patients not taking 
ART (age: 43.34±0.91). Being a male and African American was highly associated with 
the use of ART, as compared to being a female or white (P value: < 0.0001; 0.00119). 
People living in the Northeast were more likely to take ART than individuals living 
in other regions in the United States (P value: 0.0032). Among enabling components, 
difficulty in receiving medical care and having non-public insurance coverage were 
associated with not taking ART (P value: 0.0851; 0.0013). Having private insurance 
coverage was positively correlated with nonuse of ART (odds ratio: 0.190; 95% CI: 
0.047-0.779; P value: 0.00003). However, family income was not associated with the 
use of ART among the HIV-infected population. With respect to the health status 
in the need component, using ART was associated with reported improved health 
status in general, compared with those not using ART; however, the association was 
not statistically significant. CONCLUSIONS: Predisposing and enabling factors were 
found to be significantly associated with ART usage; however, need factors were not 
found to be significant. More effort is needed to improve the healthcare utilization 
inequality among minority populations.
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OBJECTIVES: Study of drug coverage in the Republic of Kazakhstan as one of the 
most important components of medical care and an important measure of social 
support of citizens. METHODS: The List of drugs for purchase in 2014 by Single 
Distributor “SK-Pharmacy “ was analyzed. The percentage of antimicrobial drugs 
for certain groups of antibiotics and synthetic antibacterial agents of different 
chemical structure was studied. The analysis of drugs from domestic and foreign 
drug manufacturers was performed. RESULTS: Among all antibacterial drugs a big 
part consisted from antibiotics - 71%, synthetic chemotherapeutic drugs amounted 
to 29%. Of the total number of antibiotics the proportion of beta-lactam antibiot-
ics amounted to 61,36%, macrolides and azalides – to 15,91%, aminoglycoside – to 
6,82%, tetracyclines and glycopeptides to 2,27%, antibiotics from other groups - 
to11,36%. Among beta-lactam antibiotics a big part consisted from semisynthetic 
penicillins with wide spectrum - 29.6%, mainly amoxicillin and its “secured forms”. 
Cephalosporins consisted 51.85% of the total number of antibiotics, and were bought 
mainly drugs of 3rd generation. Carbapenems amounted to 11.11%, monobactams 
were not bought. From the group of aminoglycosides following drugs were bought: 
amikacin, kanamycin, streptomycin, gentamicin. Synthetic antibacterial drugs of 
different chemical structures were represented mainly by fluoroquinolones (66,67%): 
moxifloxacin, ofloxacin, norfloxacin, pefloxacin , ciprofloxacin. The half (50%) of 
procured medicines are products of domestic pharmaceutical companies. The main 
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Thirty eight observational studies from 14 countries were included. Classification 
of outbreaks by setting was straightforward: 29 outbreaks occurred over a territory 
(country, region, city, etc.), 4 outbreaks in a school, 2 outbreaks at hospital, 2 in an 
isolated community and 1 at university. Costs included in this study were costs 
incurred in controlling the outbreak. Treatments with antibiotics or prophylaxis 
were reported in 10 references covering all settings. GP or specialist visits were 
reported in 3 articles (2 outbreaks over a territory and 1 outbreak in a school). Finally 
22 references reported information on hospitalisations: hospitalisation rates ranged 
from 0% to 8.8% for cases of pertussis (in 2 references, no hospitalisation occurred 
in the population exposed to the outbreak). Length of stay was reported in 2 refer-
ences: 8.9 days in hospital and 13 days in paediatric intensive care unit considering 
an outbreak at hospital, and 4 days (1 to 48 days) over a territory. CONCLUSIONS: 
The extent and the management of outbreaks differed by setting, and the economic 
burden of pertussis outbreaks was not always comparable. Nevertheless this review 
shows that the burden may be substantial.
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OBJECTIVES: Heterosexual transmission has become the major HIV transmission 
route in Guangxi China. Studies in this region reveal new cases of males newly 
infected with HIV that were both heterosexual and elderly. This study aims to 
understand the association of unsafe sex behaviors with HIV infection among 
the male clients who purchase commercial sex in in low-cost sex venues of 
Guangxi. METHODS: A cross-sectional survey study was conduct in 13 regions of 
Guangxi, among male commercial sex clients who were over 50 years old in low-
cost sex venues during October to December of 2012. Participants were interviewed 
with structured questionnaire, and had blood drawn for HIV testing. Univariate and 
multiple logistic regression models were used for data analysis. RESULTS: 3485 
participants were recruited with all blood samples tested for HIV infection. The 
prevalence of HIV in this sample was 2.96%. The risk factors associated with HIV 
infection included: being single/divorced/separated/widower (AOR:1.77, 95%CI: 1.17-
2.67, P< 0.05); aphrodisiac use (AOR:1.71, 95%CI: 1.14-2.58, P< 0.05); non-condom use 
during commercial purchased sex (AOR: 1.83, 95%CI: 1.21-2.76, P< 0.05). Also, the time 
line of last purchase of commercial is correlated to HIV infection, and the significant 
risk factor was within the last 7 days (1 week ) (AOR: 1.83, 95%CI: 1.21-2.76, P< 0.05). 
The health history of a chronic diseases was found to be a protective factor (AOR: 
0.59, 95%CI: 0.37-0.94, P< 0.05). CONCLUSIONS: Given that the high prevalence of 
HIV infection among the study group, more political policy interventions should be 
a consideration of focus with the subpopulation (middle-aged, elderly men, aphro-
disiacs and non-condom use) in rural areas of this region.
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OBJECTIVES: The cost of new HCV treatments leads payers and insurance provid-
ers to question if delaying treatment for low risk patients can be accomplished 
without adversely impacting their clinical outcome. Retrospective cohort data from 
the Veterans Administration [VA] were used to estimate the impact on patient risk 
of initiating treatment before versus after the patient’s FIB4 levels became ele-
vated. METHODS: Essentially all VA HCV patients with one or more reported FIB-4 
values during the study period were included in the analysis. Primary outcome 
measures were: time to death, and time to the first occurrence of a composite of 
liver-related clinical events. The impact of treatment initiation relative to three dif-
ferent definitions of an elevated FIB4 level was estimated using a time-dependent 
Cox proportional hazards models. RESULTS: 187,860 patients met study require-
ments. Initiating treatment before FIB4> 1.00 reduced morbidity by 41% and death 
by 36%. Initiating treatment after FIB4> 1.00 remained effective but diminished the 
morbidity risk reduction achieved to 30%. However, outcomes were worse if treat-
ment initiation was delayed until after FIB4> 3.25. The risk reductions associated 
with treatment initiated before FIB4> 3.25 were 34% for the composite event and 
45% for death, but if initiated after FIB4> 3.25 were only 11% and 25%, respectively. 
The corresponding number needed to treat [NNT] to prevent one death, is 142 for 
treatment before FIB4> 1.00 and 180 if treatment is initiated before FIB4> 3.25. The 
estimated NNT is 128 if treated after FIB4> 1.00 but increases to 325 if treated after 
FIB4> 3.25. These detrimental effects of delaying treatment until FIB4> 3.25 were 
due to a reduction in the likelihood that treated patients would achieve viral load 
suppression as well as a reduced impact of viral load suppression on morbidity 
and mortality. CONCLUSIONS: Delaying treatment until after a patient’s FIB4 level 
exceeds 3.25 had a clear detrimental effect on treatment effectiveness.
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OBJECTIVES: The U.S. Advisory Committee on Immunization Practices (ACIP) rec-
ommends pneumococcal vaccination for adults younger than 65 years with condi-
tions at increased risk of pneumococcal disease. Yet there are limited real-world 
vaccination coverage data in these high-risk adults. This study aimed to examine 
studies. Patients with MDRAB had longer length of stay than control groups across 
all studies, though findings were not always statistically significant. Within ICU 
settings, however, the differences were significant in two of three studies. Mean 
costs tended to be higher for MDRAB patients, but methods varied across studies. 
Trends in mortality rates were mixed, with many studies reporting higher mortal-
ity rates associated with MDRAB versus controls, though few reported statistically 
significant differences. Receipt of appropriate therapy was associated with lower 
mortality, though not statistically significantly different. Few studies included detail 
on treatments provided. CONCLUSIONS: Across the limited available literature, 
there is a consistent trend towards worse outcomes (higher mortality, longer LOS, 
higher costs) among patients with MDRAB versus controls. However, given the vari-
ety of study types and settings as well as the lack of multivariate analyses in most 
studies, there is considerable need for future analysis.
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OBJECTIVES: The objective of this study was to characterize U.S. national trends 
of the incidence and cost of skin and soft tissue infections (SSTIs) in 2000 and 
2012. METHODS: We performed an analysis of nationally representative data from 
the Medical Expenditure Panel Surveys (MEPS) from 2000 and 2012. SSTIs were 
defined by Clinical Classification Software code 197. Expenditures in MEPS were 
defined as payments from all sources for hospital inpatient care, ambulatory care 
provided in offices and hospital outpatient facilities, care provided in emergency 
departments, and the retail purchase of prescribed medications. Expenditure data 
for 2000 were adjusted to 2012 dollars using the Consumer Price Index. RESULTS: 
The overall incidence of SSTIs increased 40% from 2.4 million in 2000 to 3.3 mil-
lion in 2012. From 2000 to 2012, the incidence of patients with at least one hospi-
tal visit for SSTI increased 38%, ambulatory visits increased 46%, and emergency 
department visits increased 56%. The total spent on the treatment of SSTIs tripled, 
from $4.4 billion in 2000 to $13.8 billion in 2012. This was largely attributed to an 
8-fold increase in ambulatory expenditures for SSTIs, from $975 million in 2000 to 
$7.9 billion in 2012. From 2000 to 2012, emergency department care expenditures 
increased 130%, inpatient hospitalization expenditures increased 56%, and retail 
prescription purchases increased 18%. The average expenditures for ambulatory 
visits increased 5-fold from $253 [standard error (SE) + $33] to $1,336 (SE + $240) 
per person, and average hospital expenditures increased 10% from $20,135 (SE + 
$3,997) to $22,706 (SE + $5,234) per person, between 2000 and 2012. CONCLUSIONS: 
The clinical and economic burden of SSTIs has significantly increased in the U.S., 
largely driven by a dramatic increase in the number and costs of SSTIs managed 
in the ambulatory setting.
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OBJECTIVES: Medicaid is the largest payer of HIV antiretrovirals (ARVs) in the US. 
To assess the trends in Medicaid utilization of ARVs and expenditures in the period 
1991-2014, and to compare the utilization and reimbursement rates of generic and 
brand ARVs in the study period. METHODS: ARVs data were gathered from the Food 
and Drug Administration website. Utilization and expenditure data were collected 
from the Center for Medicare and Medicaid Services website. The unit of analysis 
was the defined daily dose (DDD). Descriptive analyses were performed to assess the 
Medicaid ARVs utilization, reimbursement rate, and average reimbursement per 30 
DDD. RESULTS: Utilization of HIV ARVs in Medicaid increased over the study period 
from 21,000 30 DDD in Q1-1991 to 930,000 30 DDD in Q2-2014. Further, utilization 
of generic ARVs in Medicaid increased from 58 30 DDD in Q4 2004 to 93,000 30 DDD 
in Q2 2014. Likewise, Medicaid annual expenditures on ARVs increased from $5.2 
million in Q1 1991 to $702 million in Q2 2014. During the study period, 7 ARVs out of 
35 ARV products had generic competition in Medicaid program. The market share 
of generic ARVs increased from 8.2% in the first quarter of their launch to 89.5% by 
the end of the 3rd year after the generic entry into the market. The average Medicaid 
reimbursement rate for generics was 81% of the brand reimbursement rate at the 
first quarter of the generic launch, and decreased to 76% by the end of the 3rdyear 
after generic market entry. CONCLUSIONS: Several factors may explain Medicaid 
ARVs utilization and expenditures during the study period including the number 
and type (i.e. generics and brands) of FDA ARV approvals, the Medicaid generic 
drug utilization rate, changes in therapeutic guidelines, and states’ policies and 
regulations regarding Medicaid ARVs coverage and reimbursement mechanisms.
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OBJECTIVES: Pertussis (whooping cough) is an upper respiratory infection, caus-
ing uncontrollable and severe coughing. Pertussis outbreaks are associated to a 
substantial increase in resource use that may vary depending on the setting. This 
study aims at better understanding the economic burden of pertussis outbreaks, 
by setting. METHODS: A systematic review of literature on pertussis outbreaks was 
conducted, including references published between 2011 and 2014, using Medline, 
Embase, the Cochrane library and relevant websites as potential sources. All pop-
ulation-based studies reporting information about epidemiology, burden or costs 
of pertussis outbreaks were included, without geographical restriction. RESULTS: 
